Skip to main content
main-content

18-06-2021 | ASCO 2021 | Conference coverage | Video

Additional insights from JAVELIN Bladder 100

share
SHARE

Petros Grivas outlines the latest analyses of the JAVELIN Bladder 100 study of maintenance avelumab in metastatic urothelial cancer, including the assessment of efficacy by clinical and molecular subgroups and by the post-chemotherapy treatment-free interval, as well as data on time to end of subsequent therapy (6:30).

00:00 - JAVELIN Bladder 100 overview
01:15 - Efficacy by subgroups
02:37 - Efficacy by treatment-free interval
03:58 - Time to end of next-line therapy

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.